{"id":"NCT01914666","sponsor":"Eli Lilly and Company","briefTitle":"An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain","officialTitle":"Phase 3 Clinical Study of Duloxetine Hydrochloride in Patients With CLBP - Open Label Long Term Extension Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2013-08-02","resultsPosted":"2016-01-27","lastUpdate":"2016-01-27"},"enrollment":151,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Back Pain Lower Back Chronic"],"interventions":[{"type":"DRUG","name":"Duloxetine","otherNames":["Cymbalta","LY248686"]}],"arms":[{"label":"Duloxetine","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess the long term safety of duloxetine in participants with Chronic Low Back Pain (CLBP).","primaryOutcome":{"measure":"Number of Participants With Drug Related Adverse Events (AEs) or Any Serious AE's","timeFrame":"Week 53","effectByArm":[{"arm":"Na√Øve","deltaMin":42,"sd":null},{"arm":"Rollover (Pre-Placebo)","deltaMin":16,"sd":null},{"arm":"Rollover (Pre-Duloxetine 60 mg)","deltaMin":18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":31},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":151},"commonTop":["Nasopharyngitis","Somnolence","Contusion","Nausea","Constipation"]}}